{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:28:25Z","timestamp":1788931705073,"version":"build-2803163510"},"reference-count":36,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>In recent years, several randomized controlled trials have been published regarding cervical cancer therapy and significantly changed the treatment landscape. Recent advances have improved the treatment options and allow personalized treatment concepts with escalation of treatment in high-risk disease and de-escalation with reduction in morbidity in selected low-risk patients. This review aims to provide a comprehensive analysis of the latest landmark studies that are poised to significantly influence clinical practice. Personalized treatment concepts with careful patient selection allow de-escalation in the surgical treatment of cervical cancer. In low-risk cervical cancer patients (lesions of \u22642 cm with limited stromal invasion), simple hysterectomy (SH) was non-inferior to radical hysterectomy in terms of 3-year incidence of pelvic recurrence and was associated with a lower risk of urinary incontinence or retention and improved sexual health and quality of life. Furthermore, sentinel lymphadenectomy is constantly replacing systematic pelvic lymphadenectomy in patients with low-risk cervical cancer. In addition, further studies are necessary to clarify the role of postoperative therapy for patients with intermediate-risk cervical cancer. Starting in 2008, the EMBRACE studies assess the role of Image guided adaptive brachytherapy (IGABT) in LACC in addition to modern external beam radiotherapy concurrent to chemotherapy. The publication of the results of the EMBRACE I prospective study established MRI guided IGABT as state-of-the-art brachytherapy for LACC. EMBRACE II and additional prospective studies emerging from this consortium will address important questions in modern radiotherapy for LACC. Immune checkpoint inhibitors (CPIs) have been evaluated across various clinical settings and are expected to be utilized in numerous scenarios due to several positive randomized trials. Particularly, the combination of platinum-based chemotherapy and pembrolizumab, with or without bevacizumab, has been established as the new standard treatment for primary metastatic or recurrent PD-L1 positive high-risk cervical cancer. In locally advanced cervical cancer, two new treatment escalation regimens\u2014neoadjuvant chemotherapy and adjuvant CPI therapy\u2014have been evaluated in addition to chemoradiation. Furthermore, antibody-drug conjugates, such as tisotumab-vedotin, represent a promising future therapeutic option for recurrent cervical cancer.<\/jats:p>","DOI":"10.3390\/jpm15110523","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T17:32:01Z","timestamp":1762191121000},"page":"523","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel Treatment Concepts for Cervical Cancer\u2014Moving Towards Personalized Therapy"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0289-3738","authenticated-orcid":false,"given":"Melina","family":"Danisch","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Division of General Gynecology and Gynecological Oncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Postl","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Division of General Gynecology and Gynecological Oncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1938-1574","authenticated-orcid":false,"given":"Thomas","family":"Bartl","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Division of General Gynecology and Gynecological Oncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2948-8129","authenticated-orcid":false,"given":"Christoph","family":"Grimm","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Division of General Gynecology and Gynecological Oncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Sturdza","sequence":"additional","affiliation":[{"name":"Department of Radiooncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Concin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Division of General Gynecology and Gynecological Oncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9649-4505","authenticated-orcid":false,"given":"Stephan","family":"Polterauer","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Division of General Gynecology and Gynecological Oncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis","volume":"8","author":"Arbyn","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_2","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","unstructured":"DGGG, and DKG (2025, March 05). AWMF S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom. Available online: https:\/\/register.awmf.org\/de\/leitlinien\/detail\/032-033OL."},{"key":"ref_4","unstructured":"(2025, March 08). Krebs in Deutschland fu\u0308r 2019\/2020, Berlin. Available online: https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/krebs_in_deutschland_node.html;jsessionid=CBD18C719CEBE68AD0F1AF7AB03A9E5F.1_cid372."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa2308900","article-title":"Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer","volume":"390","author":"Plante","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100001","DOI":"10.1016\/j.ijgc.2024.100001","article-title":"Minimally invasive compared to open surgery in patients with low-risk cervical cancer following simple hysterectomy: An exploratory analysis from the Gynecologic Cancer Intergroup\/Canadian Cancer Trials Group CX.5\/SHAPE trial","volume":"35","author":"Plante","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1136\/ijgc-2024-005941","article-title":"Assessing minimally invasive simple hysterectomy in low-risk cervical cancer: Set-up for the LASH trial","volume":"34","author":"Bizzarri","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/ijgc-2022-004092","article-title":"Proof-of-concept randomized phase II non-inferiority trial of simple versus type B2 hysterectomy in early-stage cervical cancer \u22642 cm (LESSER)","volume":"33","author":"Carneiro","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/ijgc-2021-002921","article-title":"ConCerv: A prospective trial of conservative surgery for low-risk early-stage cervical cancer","volume":"31","author":"Schmeler","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMoa1806395","article-title":"Minimally invasive versus abdominal radical hysterectomy for cervical cancer","volume":"379","author":"Ramirez","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ygyno.2024.06.015","article-title":"Sentinel lymph node pathological ultrastaging: Final outcome of the Sentix prospective international study in patients with early-stage cervical cancer","volume":"188","author":"Kocian","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2021.10.074","article-title":"Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer: A post-hoc analysis of SENTICOL I and SENTICOL II cohorts","volume":"164","author":"Balaya","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ygyno.2022.11.017","article-title":"Stratification of lymph node metastases as macrometastases, micrometastases, or isolated tumor cells has no clinical implication in patients with cervical cancer: Subgroup analysis of the SCCAN project","volume":"168","author":"Kim","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2023.01.014","article-title":"Role of adjuvant therapy in intermediate-risk cervical cancer patients\u2014Subanalyses of the SCCAN study","volume":"170","author":"Cibula","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/ijgc-2022-003918","article-title":"CERVANTES: An international randomized trial of radical surgery followed by adjuvant (chemo)radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEGOG-CX-05; ENGOT-CX16)","volume":"32","author":"Cibula","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.radonc.2016.03.011","article-title":"Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study","volume":"120","author":"Sturdza","year":"2016","journal-title":"Radiother. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S1470-2045(20)30753-1","article-title":"MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): A multicentre prospective cohort study","volume":"22","author":"Tanderup","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1136\/ijgc-2020-001973","article-title":"Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB\u2013IVA: Oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study","volume":"30","author":"Marnitz","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ijgc-2022-003394","article-title":"Oncologic outcomes of surgical para-aortic lymph node staging in patients with advanced cervical carcinoma undergoing chemoradiation","volume":"32","author":"Nasioudis","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/ijgc-2022-004223","article-title":"PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): A GINECO, ENGOT, and GCIG study","volume":"33","author":"Martinez","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S1470-2045(23)00147-X","article-title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): An international, open-label, randomised, phase 3 trial","volume":"24","author":"Mileshkin","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1200\/JCO.2024.42.16_suppl.5504","article-title":"Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG Oncology\/RTOG-0724\/GOG-0724","volume":"42","author":"Jhingran","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): A randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): A randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(24)01438-7","article-title":"Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): An international, multicentre, randomised phase 3 trial","volume":"404","author":"McCormack","year":"2024","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1136\/ijgc-2024-005572","article-title":"Are we making progress in curing advanced cervical cancer\u2014Again?","volume":"34","author":"Lindegaard","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): A randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1200\/JCO.23.00720","article-title":"Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205\/GOG-3024\/ENGOT-cx8 Study","volume":"41","author":"Vergote","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Zhai, C., Cui, Y., Guo, L., Chen, C., Song, Y., Zhong, J., and Wang, Y. (2024). Progress in the study of antibody-drug conjugates for the treatment of cervical cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1395784"},{"key":"ref_35","first-page":"S548","article-title":"716MO\u2014Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer","volume":"35","author":"Wang","year":"2024","journal-title":"Larvol Clin."},{"key":"ref_36","unstructured":"National Library of Medicine (2025, July 23). Available online: https:\/\/clinicaltrials.gov."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/11\/523\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T17:49:46Z","timestamp":1762192186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/11\/523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jpm15110523"],"URL":"https:\/\/doi.org\/10.3390\/jpm15110523","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}